Tirzepatide in Sweden: import rules

In Sweden, tirzepatide is available on prescription under the brand Mounjaro for both type-2 diabetes and weight management. Mounjaro is centrally authorised by the European Medicines Agency^[1] and valid across the EU, which means Swedish clinicians can prescribe it and licensed Swedish pharmacies can dispense it. Importing tirzepatide into Sweden from outside the European Economic Area sits in a different legal category, and the rules that apply there are the focus of this article.

What the EMA authorisation means in Sweden

The European Medicines Agency granted Mounjaro a central marketing authorisation on 15 September 2022^[1], covering both type-2 diabetes (as an adjunct to diet and exercise when metformin is inappropriate or alongside other antidiabetic medicines) and weight management (for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related comorbidity such as hypertension, dyslipidaemia, obstructive sleep apnea, or cardiovascular disease). The current product information reflects revision 20, dated 26 February 2026.

A central authorisation is one decision that applies across all EU member states, including Sweden. Eli Lilly Nederland B.V. holds the marketing authorisation (ATC code A10BX16). The consequence for Swedish patients is practical: Mounjaro can be prescribed by any Swedish clinician with prescribing authority for the relevant indication and dispensed at any licensed Swedish pharmacy. The product is prescription-only; it is not available over the counter. See the tirzepatide regulation overview for the cross-country picture.

TLV (Tandvårds- och läkemedelsförmånsverket), the Swedish pharmaceutical benefits agency, determines whether a product qualifies for the national high-cost protection scheme (högkostnadsskyddet). Based on publicly available TLV decision records, Mounjaro does not currently appear in the general or restricted subsidy categories, which means patients typically pay the full price out of pocket unless a specific regional or employer scheme covers the cost. TLV positions can change; patients and prescribers should verify the current subsidy status directly with their pharmacist or with TLV.

Bringing tirzepatide into Sweden from another EEA country

Patients travelling within the EEA with their own prescribed Mounjaro are in a different position from someone attempting to order it online from a non-EEA vendor. Under EU Directive 2011/24/EU on cross-border healthcare, EU and EEA member states recognise each other's prescriptions in principle, though individual pharmacies retain discretion. A traveller carrying Mounjaro prescribed by their home clinician and dispensed by a licensed EEA pharmacy is generally within the rules, provided the quantity is consistent with personal use and the product remains in its original packaging with labelling intact.

The practical limit is the supply period. Bringing a few weeks of Mounjaro while on a work assignment is a different matter from attempting to import a year's supply across an EEA border. Läkemedelsverket, Sweden's Medical Products Agency, publishes guidance for travellers carrying medicines and, for unusual situations, operates a formal dispensation process for importing medicinal products for personal use where standard EEA supply channels are not available.

Importing from outside the EEA

This is where the legal position tightens. Like all prescription-only medicines in Sweden, tirzepatide cannot lawfully be imported by private individuals from non-EEA countries without specific dispensation^[2]. Under the Swedish Medicines Act (Läkemedelslagen, SFS 2015:584), the import of medicines into Sweden is reserved for licensed pharmaceutical importers. Private individuals who want to bring in a medicine through non-standard channels can apply to Läkemedelsverket for a dispensation, but the agency expects documentary evidence that the medicine is clinically necessary and that the applicant already holds a prescription from a licensed prescriber.

The dispensation route exists precisely for situations where a medicine is not accessible through normal EEA supply. Mounjaro is not in that category. It is available on prescription from Swedish clinicians and at licensed Swedish pharmacies. An application for dispensation to import Mounjaro from outside the EEA is unlikely to succeed because the authorised domestic supply route is open.

In practice, parcels of tirzepatide arriving from outside the EEA (for instance, from online vendors in the United States, the United Kingdom post-Brexit, or elsewhere) are subject to inspection by Swedish Customs (Tullverket) and may be passed to Läkemedelsverket for assessment. The recipient has no automatic right to have the goods released. Consignments determined to be unauthorised imports of a prescription medicine can be destroyed without compensation. There is also a VAT and duty dimension: goods entering Sweden from outside the EU with a declared value above SEK 0 attract import duties and VAT regardless of what they contain.

What customs flags

Tullverket applies risk-based scanning to parcels entering Sweden. Pharmaceutical products from known source countries sit on the agency's risk register. Common flags that prompt inspection include pharmaceutical packaging visible on X-ray scanning, declared values inconsistent with parcel weight, sender addresses associated with online pharmacies or supplement vendors, and labelling in non-EEA languages without accompanying prescription documentation.

If a parcel is stopped, the recipient receives a notification and may be invited to provide documentation, including a prescription and evidence that the medicine came from a licensed source. Without that documentation, the shipment is unlikely to be released. A first-time seizure of a small personal quantity generally does not lead to criminal prosecution under Swedish law. Repeat imports or large quantities attract more scrutiny under the Medicines Act provisions on unlawful import.

The grey-market picture for tirzepatide

Grey-market vials labelled as tirzepatide and sold online under designations such as "for research use only" present the same supply-quality problems seen across the GLP-1 class. Läkemedelsverket treats these products as unauthorised medicines, not as research chemicals. The "research use only" label does not exempt them from medicines regulation when sold and used for human administration.

The quality risk is not theoretical. Independent testing of grey-market peptide products as a category has documented failures on purity, identity and contamination. A product that arrives labelled as tirzepatide may contain a different substance, the wrong concentration, or bacterial contamination from non-sterile manufacturing. Mounjaro, the authorised product, is manufactured under Good Manufacturing Practice standards to a defined specification. Grey-market alternatives operate outside that system entirely. See the tirzepatide grey-market risk guide for more detail on what independent testing of such products finds.

What this is not

This article does not address compounded tirzepatide. Compounding is a specific route in US pharmacy law that allowed large-scale preparation of tirzepatide during shortage periods; the FDA has since declared the shortage resolved and large-scale compounding is no longer permitted under enforcement discretion in the US. Swedish compounding pharmacies operate under their own distinct rules and compounded tirzepatide is not an established route in Sweden. Nor does this article address the Zepbound brand, which is a US presentation for chronic weight management and obstructive sleep apnea that is not authorised in the EEA. In the EU and EEA, tirzepatide is sold solely as Mounjaro for its two authorised indications: type-2 diabetes and weight management.

This article also does not provide dosing guidance. The literature on tirzepatide trials reports weight-management doses ranging from 5 mg to 15 mg weekly, administered by subcutaneous injection. The specific dose for a given patient depends on their indication, tolerability, and clinical context. Those are decisions for a prescriber who knows the patient's history, not for an import-rules article.

For the practical next step: if you are in Sweden and considering tirzepatide, the correct route is a referral to your husläkare (GP) or relevant specialist for assessment under the authorised indications. For regulatory details on other Nordic countries and the EU more broadly, see the tirzepatide regulation hub and the Sweden regulatory overview.